SuperworthPalatin Technologies PTN
- Market cap
- $9.1M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Palatin Technologies' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.1M+142% | $2M+98% | $0 | $350K−80% | n/a | n/a | $0 | $0 | n/a | $116K | $3.9M | $300.8K | |
| Cost of revenue | $0 | $97.6K−1% | $0 | $0 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | $2.1M+169% | $1.9M+109% | $0 | $350K−79% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $5M−17% | $5.6M+27% | $7.2M+48% | $4.7M−37% | $5.7M+15% | $3.4M−38% | $3.8M−48% | $2M−58% | $2.5M−56% | $4.3M+26% | $3.5M−6% | $2M+2% |
| SG&A | $3.2M−9% | $3M−5% | $2M−43% | $4M−21% | $2M−37% | $1.7M−45% | $1.5M−28% | $2.6M−34% | $1.7M−18% | $3.1M+86% | $2M+35% | $2.7M+3% |
| −$6.1M−30% | $1.2M | −$9.2M+26% | −$8.3M−23% | −$7.8M+27% | −$2.6M | −$4.8M−48% | −$2.3M−73% | $4.7M | −$7.3M+181% | −$1.6M−67% | −$4.4M+95% | |
| Interest expense | $10.9K+13% | $1.6K−71% | $1.3K−64% | $3.4K+126% | $5.9K−45% | $3.8K+137% | $1.8K+43% | $3.5K+3% | $2K−66% | $498−87% | $1.3K−29% | $3K−15% |
| Pre-tax income | n/a | −$7.8M+299% | −$8.4M−3% | −$8.3M−16% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| n/a | $0 | $0 | $0 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$5.2M−37% | −$7.8M | −$8.4M−3% | −$8.3M−16% | −$7.8M+50% | −$2.4M−69% | −$4.8M−43% | −$2.2M−73% | $4.7M | −$7.3M+197% | −$1.4M−70% | −$4.4M+96% |
| −$21.50−50% | −$28.00 | −$26.50−30% | n/a | −$19.71−8% | −$5.92−79% | −$9.13−66% | −$2.72 | $4.26 | −$2.86−52% | −$0.37−96% | −$1.11−59% | |
| 243.4K+26% | 282K+31% | 315.8K+38% | n/a | 396.9K+63% | 412.7K+46% | 526.9K+67% | 819.7K | 1.1M+177% | 2.5M+515% | 3.9M+643% | 3.9M+378% |
Gross profit: 19 periods, Q1 FY20 to Q4 FY24: not printed by the filing, worked out from its own lines.
Pre-tax income: Q1 FY11: 6 months less the 3 months printed beside them.
Income tax: Q1 FY11: 6 months less the 3 months printed beside them.
EPS, diluted: 31 periods, Q1 FY11 to Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: 9 periods, Q4 FY11 to Q4 FY26: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY17 and Q4 FY18: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Palatin Technologies' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PTNPalatin Technologies | $9.1M | n/m | 7.4× | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Palatin Technologies
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .